CSE: PILL | OTC: CTABF | FSE: TBF1
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
– Opens the Door for Canadian and International Sales and White Labeling –
Toronto, Ontario — April 23, 2019 — Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the “Company” or “Canntab”) is pleased to announce that by virtue of FSD Pharma Inc. (“FSD”), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a “sale for medical purposes” licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the “FSD Licence”), Canntab is very close to being in a position to sell its products and generate revenue. The FSD License allows Canntab to produce samples of capsules containing CBD and/or THC, which, once approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD’s Health Canada approved facility in Cobourg, Ontario. In addition, the FSD Licence, when combined with an export permit, which FSD intends to acquire as soon as possible, will also allow Canntab to sell its products in foreign markets.
Sign up for our monthly newsletter and keep up to date as we move toward product sales in 2019!